Search Results
Dec 16, 2025, 20:00 ET Antengene Expands XPOVIO® Indications in Malaysia with Approval in Diffuse Large B-cell Lymphoma
subsequently submitted to the Hong Kong Stock Exchange.For more information, please contact:Investor Contacts: Donald LungE-mail: [email protected] BD Contacts:Ariel
More news about: Antengene Corporation Limited
Dec 16, 2025, 17:00 ET Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program
and neck squamous cell carcinoma (HNSCC) and the Phase 1/2 trial evaluating patients with checkpoint inhibitor refractory or relapsed non-small cell lung cancer (NSCLC) in combination with Keytruda. The Company also provided a brief progress update on the expansion cohorts investigating ozekibart in combination
More news about: Inhibrx Biosciences, Inc.
Dec 16, 2025, 13:17 ET Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B
Conference on Lung Cancer, demonstrating clinically meaningful outcomes for firmonertinib in EGFR PACC mutant non-small cell lung cancer, advancing
More news about: USA News Group
Dec 16, 2025, 08:30 ET Allink Biotherapeutics Completes $47M Extension Rounds of Series A to Accelerate Clinical Programs and Novel Platforms Development
early clinical data for ALK202 have provided preliminary support of the EGFR/cMET bispecific ADC's potential as a cornerstone therapy in non-small cell lung cancer. Furthermore, the program is being expanded into clinical evaluation of a broader range of biomarker-defined tumor types and patient populations.AllinkBio
More news about: Allink Biotherapeutics
Dec 16, 2025, 05:02 ET Kick the Nic in 2026: American Lung Association Offers Support to Help People Quit All Nicotine and Tobacco Products for Good
www.lung.org/openenrollment.About the American Lung AssociationThe American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research. The work of the American Lung Association is focused on four strategic
More news about: American Lung Association
Dec 16, 2025, 02:30 ET Allink Biotherapeutics Completes $47M Extension Rounds of Series A to Accelerate Clinical Programs and Novel Platforms Development
early clinical data for ALK202 have provided preliminary support of the EGFR/cMET bispecific ADC's potential as a cornerstone therapy in non-small cell lung cancer. Furthermore, the program is being expanded into clinical evaluation of a broader range of biomarker-defined tumor types and patient populations.AllinkBio
More news about: Allink Biotherapeutics
Dec 15, 2025, 16:00 ET AZmed Expands Into CT Imaging With CE-Marked AZnod, An AI Tool for Lung Nodule Detection and the First Product in the Rayscan® Line
AZnod is designed to aid lung cancer screening programs by providing standardized detection and comprehensive characterization of pulmonary nodules on CT scans.Lung cancer screening procedures place an interpretive load on medical imaging teams
More news about: AZmed
Dec 15, 2025, 11:46 ET Brayton Purcell LLP Highlights Massachusetts Safety Alert After State's First Silicosis Case in Artificial Stone Industry
Silicosis is a progressive, incurable lung disease caused by inhaling silica particles. Crystalline silica artificial stone—also referred to as "quartz" or "engineered stone"—contains at least
More news about: Brayton Purcell LLP
Dec 15, 2025, 11:23 ET Detect-ION Launches Collaborative Project to Develop Breath-Based Diagnostics for Pneumonia-Causing Pathogens
develop a non-invasive breath test for detecting Pseudomonas aeruginosa – one of the leading causes of pneumonia in lung transplant recipients and patients with structural lung diseases.
More news about: Detect-ION
Dec 15, 2025, 08:45 ET Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic
breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms
More news about: Anixa Biosciences, Inc.
Dec 15, 2025, 07:00 ET EYLSIA NICOLAS TRIUMPHS WITH PATENT AWARD, CHART RECORDS, AND INSPIRING JOURNEY OF RESILIENCE
to a year defined by extraordinary resilience and artistic achievement. In 2025, Nicolas faced the daunting challenge of losing 20% of her lung capacity and sustaining damage to her vocal cords. Rather than retreat, she turned to her pioneering sound technology and artificial intelligence
More news about: Eylsia Nicola
Dec 12, 2025, 16:29 ET Oklahoma Proton Center lauds results of groundbreaking clinical study
state-of-the-art cancer treatment. The center treats over 750 patients a year across multiple disease sites including head and neck, brain, breast, prostate, lung, esophageal, lymphoma, sarcoma, and pediatric cancers. For more information about proton therapy or to see if you are a candidate please visit
More news about: Oklahoma Proton Center
Dec 12, 2025, 11:45 ET Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer
estimates.4About Breast CancerBreast cancer is the second most commonly diagnosed cancer worldwide (following lung cancer), according to GLOBOCAN. The estimated 2.3 million new cases indicate that close to 1 in every 4 cancers diagnosed in 2022 is breast cancer.
More news about: Eli Lilly and Company
Dec 12, 2025, 10:47 ET Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance
cancers when combining two checkpoint inhibitors[3]. Multiple institutions initiated therapeutic vaccine trials targeting pancreatic and lung cancers, with early pancreatic vaccine data showing immune responses associated with reduced recurrence risk[4].Oncolytics Biotech
More news about: USA News Group
Dec 12, 2025, 10:30 ET NanOlogy Unveils Drug Development Program for Rare Pediatric Brainstem Tumor
clinical programs have advanced LSAM investigational drugs in multiple solid tumors including pancreas, lung, bladder, peritoneal, ovarian, prostate, and dermal cancers. Feasibility of the Purcision™ platform has been established in taxanes, platins, tyrosine
More news about: NanOlogy, LLC
Dec 12, 2025, 08:45 ET Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025
2024, highlighting a significant unmet need. Lung cancer is the leading cause of cancer deaths and there are there are over 200,000 new cases expected in the U.S. in 2025 and over 2 million cases globally. NSCLC accounts for approximately 85% of all lung cancer cases. EGFR targeting therapies including
More news about: Actinium Pharmaceuticals, Inc.
Dec 12, 2025, 08:32 ET Flu Season Predicted to Be "Nasty This Winter." IQ AIR Can Help
LifeBridge's Lung Immunity Support Is a Tool for Respiratory Health During a Busy Holiday SeasonFORT LAUDERDALE, Fla., Dec. 12, 2025 /PRNewswire/ -- New report finds the flu season could
More news about: LifeBridge
Dec 12, 2025, 07:00 ET Insilico Medicine and TaiGen Achieves License Agreement to Develop and Commercialize AI-driven PHD Inhibitor for Anemia of Chronic Kidney Disease (CKD)
this strategic partnership with Insilico Medicine. The innovation Insilico brings through its generative AI platform is truly impressive." said Kuo-Lung Huang, Chairman of TaiGen Biotechnology. "With over a million dialysis patients in Mainland China, the PHD inhibitor
More news about: Insilico Medicine
Dec 11, 2025, 18:02 ET Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants
breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms
More news about: Anixa Biosciences, Inc.
Dec 11, 2025, 13:06 ET Pillar Biosciences and AstraZeneca Expand Liquid Biopsy Access Partnership to China
for approximately 24% of new global cancer cases and 30% of cancer-related deaths, according to the World Health Organization's GLOBOCAN 2022 report. Lung, colorectal, and liver cancers remain among the most prevalent, and access to early detection and molecular diagnostics continues to be a significant
More news about: Pillar Biosciences, Inc.
Dec 11, 2025, 10:17 ET Platform Technologies Drive $211B Surge in Precision Cancer Treatment
cancers, GT Biopharma is developing GTB-5550, which targets B7H3, a protein commonly found across various solid tumor types including breast, lung, ovarian, pancreatic, bladder, and prostate cancers. The company expects to submit its regulatory application to begin human trials of GTB-5550 in late
More news about: Equity Insider
Dec 11, 2025, 10:15 ET TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
clinical trial of TTI-101 in idiopathic pulmonary fibrosis. The study was designed to assess safety, pharmacokinetics, and exploratory outcomes related to lung function. After reviewing the preliminary safety data and exploratory efficacy results, including changes in Forced Vital Capacity (FVC), the Company
More news about: Faruqi & Faruqi, LLP
Dec 11, 2025, 10:00 ET Bank of America Chicago Marathon Shatters Another Record: $47.1 Million for Charity
to running the Bank of America Chicago Marathon in honor of his wife Paula who had been diagnosed with lung cancer in April. Jim rallied his network of friends and family raising funds for local lung cancer researcher at Northwestern University, supporting the American Cancer Society's mission improving
More news about: Bank of America Corporation
Dec 11, 2025, 09:29 ET The PHERGuide study demonstrates the utility of circulating tumor DNA for the early detection and real-time monitoring of localized HER2+ breast cancer
antibody-drug conjugate patritumab deruxtecan (HER3-DXd) in patients with brain metastases derived from HER2+ breast cancer [and] advanced non-small cell lung cancer, as well as in patients with leptomeningeal disease of any solid tumor.Now, this sub-analysis examines the efficacy of this drug in those
More news about: MEDSIR
Dec 11, 2025, 09:00 ET Phoenix Children's Earns National Recognition as a Pediatric Pulmonary Hypertension Network Site
the lungs, placing significant strain on the heart. It often affects infants born extremely prematurely — sometimes as early as 24 to 26 weeks — when lung development halts outside the womb. Many young patients also face additional diagnoses such as Down syndrome, bronchopulmonary dysplasia (BPD), congenital
More news about: Phoenix Children's